Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions
Nutrients · 14.07.2025 · 17 (14) · 2310
DOI: 10.3390/nu17142310 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 14.07.2025. Verfasst von Mariana Souto und 2 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Unidade Local de Saúde do Alto Ave, 4835-044 Guimarães, Portugal. Hauptthemen laut MEDLINE: Obesity, Weight Loss, Inflammation, Carcinogenesis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Obesity is a growing global health concern and a modifiable risk factor for multiple pancreatic diseases, including acute pancreatitis (AP), chronic pancreatitis (CP), and pancreatic cancer (PC). While these conditions have distinct clinical courses, obesity contributes to their pathogenesis through shared mechanisms, such as visceral adiposity, systemic inflammation, insulin resistance, and ectopic pancreatic fat deposition.
Methods
This narrative review synthesizes current evidence from clinical, epidemiological, and mechanistic studies exploring the relationship between obesity and pancreatic diseases. We also critically evaluate the effects of weight loss interventions—including lifestyle modifications, pharmacologic therapies, endoscopic approaches, and bariatric surgery—on the risk and progression of disease.
Results
Obesity increases the risk and severity of AP via mechanisms such as gallstone formation, hypertriglyceridemia, and lipotoxicity. In CP, obesity-related intrapancreatic fat and metabolic dysfunction may influence disease progression, although some data suggest a paradoxical protective effect. In PC, obesity accelerates tumorigenesis through chronic inflammation, adipokine imbalance, and activation of oncogenic signaling pathways. Weight loss interventions, particularly bariatric surgery and incretin-based therapies (e.g., GLP-1 receptor agonists and dual agonists such as tirzepatide), show promising effects in reducing disease burden and improving metabolic and inflammatory profiles relevant to pancreatic pathology.
Conclusions
Obesity plays a multifaceted role in the pathophysiology of pancreatic diseases. Therapeutic strategies targeting weight loss may alter disease trajectories, improve outcomes, and reduce cancer risk. Further research is needed to define optimal intervention strategies and to identify and validate biomarkers for personalized risk assessment and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gastroenterology Department, Unidade Local de Saúde do Alto Ave, 4835-044 Guimarães, Portugal.
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4704-553 Braga, Portugal.
- ICVS/3B's-PT Government Associate Laboratory, 4710-057 Braga, Portugal.
ORCID-Profile: Mariana Souto, José Cotter
Zitieren
APA
Souto, M., Cúrdia Gonçalves, T., & Cotter, J. (2025). Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions. Nutrients, 17(14), 2310. https://doi.org/10.3390/nu17142310
Vancouver
Souto M, Cúrdia Gonçalves T, Cotter J. Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions. Nutrients. 2025;17(14):2310. doi:10.3390/nu17142310
BibTeX
@article{Souto2025,
author = {Souto, Mariana and Cúrdia Gonçalves, Tiago and Cotter, José},
title = {Obesity and Pancreatic Diseases: From Inflammation to Oncogenesis and the Impact of Weight Loss Interventions},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {14},
pages = {2310},
doi = {10.3390/nu17142310}
}
EUVIMED